HC Wainwright Has Positive Estimate for COYA Q3 Earnings

Coya Therapeutics, Inc. (NASDAQ:COYA - Free Report) - Stock analysts at HC Wainwright raised their Q3 2025 EPS estimates for shares of Coya Therapeutics in a report released on Monday, May 19th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.24) per share for the quarter, up from their prior forecast of ($0.50). The consensus estimate for Coya Therapeutics' current full-year earnings is ($1.15) per share. HC Wainwright also issued estimates for Coya Therapeutics' Q4 2025 earnings at ($0.51) EPS and FY2025 earnings at ($1.41) EPS.

Other equities analysts also recently issued reports about the company. Chardan Capital reissued a "buy" rating and set a $14.00 target price on shares of Coya Therapeutics in a research note on Tuesday, May 13th. Wall Street Zen lowered Coya Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday. Finally, D. Boral Capital reissued a "buy" rating and issued a $18.00 target price on shares of Coya Therapeutics in a report on Tuesday, April 22nd. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $17.00.

Coya Therapeutics Stock Up 3.3%

NASDAQ COYA traded up $0.19 during trading hours on Wednesday, hitting $5.90. 12,660 shares of the stock were exchanged, compared to its average volume of 72,712. The company has a market cap of $98.68 million, a price-to-earnings ratio of -9.08 and a beta of 0.49. Coya Therapeutics has a 12-month low of $4.65 and a 12-month high of $10.24. The stock has a 50-day moving average of $5.97 and a 200 day moving average of $6.12.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.44) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.44). The firm had revenue of $257.88 million during the quarter, compared to analyst estimates of $2.63 million.

Institutional Trading of Coya Therapeutics

Large investors have recently made changes to their positions in the stock. DME Capital Management LP grew its position in shares of Coya Therapeutics by 29.2% in the fourth quarter. DME Capital Management LP now owns 1,646,440 shares of the company's stock valued at $9,434,000 after purchasing an additional 372,414 shares during the period. AIGH Capital Management LLC lifted its holdings in shares of Coya Therapeutics by 85.0% during the 4th quarter. AIGH Capital Management LLC now owns 1,201,152 shares of the company's stock valued at $6,883,000 after acquiring an additional 551,725 shares in the last quarter. CM Management LLC grew its stake in shares of Coya Therapeutics by 25.0% in the first quarter. CM Management LLC now owns 200,000 shares of the company's stock valued at $1,294,000 after buying an additional 40,000 shares in the last quarter. Dauntless Investment Group LLC acquired a new stake in Coya Therapeutics in the first quarter valued at approximately $1,083,000. Finally, Geode Capital Management LLC increased its stake in Coya Therapeutics by 5.8% during the 4th quarter. Geode Capital Management LLC now owns 150,576 shares of the company's stock worth $863,000 after buying an additional 8,267 shares during the period. Institutional investors and hedge funds own 39.75% of the company's stock.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.